中国继续医学教育
中國繼續醫學教育
중국계속의학교육
CHINA CONTINUING MEDICAL EDUCATION
2014年
8期
143-146
,共4页
闫珺%张菊新%张艳%吴衡慧
閆珺%張菊新%張豔%吳衡慧
염군%장국신%장염%오형혜
奈达铂%多西他赛%妇科恶性肿瘤%复发
奈達鉑%多西他賽%婦科噁性腫瘤%複髮
내체박%다서타새%부과악성종류%복발
Nedaplatin%Docetaxel%Gynecologic malignant tumor
目的:探讨奈达铂联合多西他赛治疗铂类敏感型复发的妇科恶性肿瘤的近期疗效和安全性。方法回顾性分析39例具有可测量病灶的铂类敏感型复发的妇科恶性肿瘤患者,采用奈达铂联合多西他赛两药联合方案治疗,奈达铂70~80 mg/m2,第1天静脉滴注,多西他赛70~75 mg/m2,第1天静脉滴注,3周重复,所有患者均完成4~6个周期化疗。采用实体肿瘤治疗疗效评估标准(RECIST)进行疗效评估,不良反应依据 WHO 抗癌药物毒性表现及分级标准进行评价。结果39例患者中…完全缓解8例、部分缓解19例,治疗总有效率为69.23%。患者中…位无进展生存时间为8.2个月。主要不良反应为白细胞降低、血小板降低、血红蛋白降低、恶心、呕吐、腹泻等…,经对症治疗后均缓解或消失,未出现不可控制感染或并发多器官功能衰竭而导致死亡。结论奈达铂联合多西他赛在铂类敏感型复发的妇科恶性肿瘤的治疗中…疗效确切,严重不良反应发生率较低,可以作为铂类敏感型复发的妇科恶性肿瘤临床治疗的一种新选择。
目的:探討奈達鉑聯閤多西他賽治療鉑類敏感型複髮的婦科噁性腫瘤的近期療效和安全性。方法迴顧性分析39例具有可測量病竈的鉑類敏感型複髮的婦科噁性腫瘤患者,採用奈達鉑聯閤多西他賽兩藥聯閤方案治療,奈達鉑70~80 mg/m2,第1天靜脈滴註,多西他賽70~75 mg/m2,第1天靜脈滴註,3週重複,所有患者均完成4~6箇週期化療。採用實體腫瘤治療療效評估標準(RECIST)進行療效評估,不良反應依據 WHO 抗癌藥物毒性錶現及分級標準進行評價。結果39例患者中…完全緩解8例、部分緩解19例,治療總有效率為69.23%。患者中…位無進展生存時間為8.2箇月。主要不良反應為白細胞降低、血小闆降低、血紅蛋白降低、噁心、嘔吐、腹瀉等…,經對癥治療後均緩解或消失,未齣現不可控製感染或併髮多器官功能衰竭而導緻死亡。結論奈達鉑聯閤多西他賽在鉑類敏感型複髮的婦科噁性腫瘤的治療中…療效確切,嚴重不良反應髮生率較低,可以作為鉑類敏感型複髮的婦科噁性腫瘤臨床治療的一種新選擇。
목적:탐토내체박연합다서타새치료박류민감형복발적부과악성종류적근기료효화안전성。방법회고성분석39례구유가측량병조적박류민감형복발적부과악성종류환자,채용내체박연합다서타새량약연합방안치료,내체박70~80 mg/m2,제1천정맥적주,다서타새70~75 mg/m2,제1천정맥적주,3주중복,소유환자균완성4~6개주기화료。채용실체종류치료료효평고표준(RECIST)진행료효평고,불량반응의거 WHO 항암약물독성표현급분급표준진행평개。결과39례환자중…완전완해8례、부분완해19례,치료총유효솔위69.23%。환자중…위무진전생존시간위8.2개월。주요불량반응위백세포강저、혈소판강저、혈홍단백강저、악심、구토、복사등…,경대증치료후균완해혹소실,미출현불가공제감염혹병발다기관공능쇠갈이도치사망。결론내체박연합다서타새재박류민감형복발적부과악성종류적치료중…료효학절,엄중불량반응발생솔교저,가이작위박류민감형복발적부과악성종류림상치료적일충신선택。
Objective To study the Nedaplatin platinum joint Docetaxel in the treatment of gynecological malignant tumor of the platinum sensitive recurrence of recent efficacy and safety. Methods A retrospective analysis of 39 cases with measurable lesions of platinum sensitive patients with gynecological malignant tumor recurrence, adopt Nedaplatin oxaliplatin two drugs combination therapy, Nedaplatin platinum 70~80 mg/m2, 1 days intravenous drip, Docetaxel 70~75 mg/m2, 1 days intravenous drip, all patients were complete 4~6 cycles of chemotherapy. Using solid tumor treatment response evaluation criteria in solid tumors (RECIST) to evaluate curative effect, adverse reaction according to the WHO cancer drug toxicity and classification standard for evaluation of performance. Results 39 patients in complete remission, 8 cases, partial in 19 cases, the total effective rate was 69.23%. Patients with median progression-free survival time was 8.2 months. Main adverse reactions of low white blood cells, platelets, and lower hemoglobin, nausea, vomiting, diarrhea, ease or disappeared after symptomatic treatment, not present an infection control or complicated with multiple organ failure and death. Conclusion Nedaplatin platinum joint Docetaxel in platinum sensitive in the treatment of recurrent gynecologic malignant tumor curative effect, lower incidence of serious adverse reactions, can be used as a platinum sensitive recurrent gynecologic malignant tumor a new choice for clinical treatment.